Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
MIRA Pharmaceuticals, Inc. - Common Stock
(NQ:
MIRA
)
1.100
+0.010 (+0.92%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
211,491
Open
1.110
Bid (Size)
1.070 (20)
Ask (Size)
1.100 (11)
Prev. Close
1.090
Today's Range
1.060 - 1.119
52wk Range
0.5100 - 6.400
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game
October 03, 2024
Breakthrough Therapies And Novel Treatments - This Biopharma Is Out To Change The Game
Via
News Direct
Topics
Cannabis
Exposures
Cannabis
Why Mira Shares Are Trading Higher Today
September 27, 2024
MIRA Pharmaceuticals Inc. (NASDAQ: MIRA) shares are trading higher Friday following the announcement of promising new preclinical data for its lead development product, Ketamir-2. Here's what you need...
Via
Benzinga
Performance
YTD
-7.56%
-7.56%
1 Month
-5.17%
-5.17%
3 Month
-78.04%
-78.04%
6 Month
+28.65%
+28.65%
1 Year
-64.74%
-64.74%
More News
Read More
MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024
September 27, 2024
Via
ACCESSWIRE
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing On Early Clinical Efficacy Demonstration For Neuropathic Pain In 2025
September 19, 2024
Via
News Direct
MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025
September 18, 2024
Via
ACCESSWIRE
Peering Into Mira Pharmaceuticals's Recent Short Interest
September 11, 2024
Via
Benzinga
MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study
August 26, 2024
Via
ACCESSWIRE
(MIRA) - Analyzing Mira Pharmaceuticals's Short Interest
July 26, 2024
Via
Benzinga
MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA
September 11, 2024
Via
ACCESSWIRE
The Potential Of Ketamir-2: A Safer Treatment For Mental Health Disorders And Neuropathic Pain, IND Filing Expected By Year-End
August 27, 2024
Via
News Direct
MIRA Pharmaceuticals' Oral Ketamine Analog Achieves Complete Normalization Of Neuropathic Pain In Animal Studies
August 26, 2024
Via
Benzinga
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
August 26, 2024
Via
Benzinga
MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action
July 25, 2024
Via
ACCESSWIRE
Heico, PDD Holdings And 3 Stocks To Watch Heading Into Monday
August 26, 2024
Via
Benzinga
MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End
August 19, 2024
Via
ACCESSWIRE
MIRA Stock Earnings: Mira Pharmaceuticals Misses EPS for Q2 2024
August 13, 2024
Via
InvestorPlace
MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor
August 12, 2024
Via
ACCESSWIRE
Why Kellanova Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
August 05, 2024
Via
Benzinga
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In July 2024 – Where Do Tesla, Nvidia, Apple, CrowdStrike Rank?
August 01, 2024
Via
Benzinga
MIRA Pharmaceuticals (NASDAQ: MIRA) Reports Promising Pre-Clinical Trial Results For Mental Health Treatment, To Submit Investigational New Drug Application By End Of Year
July 29, 2024
Via
News Direct
Topics
Cannabis
Exposures
Cannabis
Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data
July 25, 2024
Via
Benzinga
Why Comcast Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
July 23, 2024
Via
Benzinga
Why Is Mira Pharmaceuticals (MIRA) Stock Down 27% Today?
July 23, 2024
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
July 23, 2024
Via
InvestorPlace
Why SAP Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
July 23, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.